資料載入中.....
|
請使用永久網址來引用或連結此文件:
https://ir.cnu.edu.tw/handle/310902800/34353
|
| 標題: | Comparison of trimodal therapy versus radical cystectomy for each stage of muscle-invasive bladder cancer |
| 作者: | Tseng, Wen-Hsin
Huang, Steven K.
Liu, Chien-Liang
Kuo, Jinn-Rung
Hun, Shun-Hsing
Chen, Chun-Hao
Su, Chia-Cheng
Wang, Jhih-Cheng
Lee, Kau-Han
Hsieh, Kun-Lin
Chiu, Allen W. |
| 貢獻者: | Chi Mei Med Ctr, Div Urol, Dept Surg
Chia Nan Univ Pharm & Sci
Chi Mei Med Ctr, Div Neurosurg, Dept Surg
Chi Mei Hosp, Div Urol, Dept Surg
Mackay Mem Hosp, Dept Urol
Natl Yang Ming Univ, Sch Med |
| 關鍵字: | Muscle-invasive bladder cancer
radical cystectomy
trimodal therapy |
| 日期: | 2021 |
| 上傳時間: | 2023-11-11 11:46:19 (UTC+8) |
| 出版者: | WOLTERS KLUWER MEDKNOW PUBLICATIONS |
| 摘要: | Purpose: Radical cystectomy (RC) has long been the standard of care for the management of muscle-invasive bladder cancer (MIBC). However, an increasing trend of bladder-sparing trimodal therapy (TMT) using maximal transurethral resection of bladder tumor, followed by radiation therapy (RT) with concomitant radiosensitizing chemotherapy, has been advocated. We compared the differences regarding long-term oncological outcomes between patients who accepted RC or TMT for MIBC. Materials and Methods: Between January 2012 and December 2018, 207 patients were diagnosed with MIBC at our center. We excluded patients with metastasis disease, received other treatments, and lost to follow-up. The patients were categorized into Group 1 (TMT) and Group 2 (RC). Both the groups with each tumor stage were compared for disease-free survival (DFS) and overall survival (OS) rates, and the risk factors for recurrence and survival were assessed. Results: In total, 58 (48.7%) patients in Group 1 underwent TMT and 61 (51.3%) patients in Group 2 underwent RC. The mean follow-up was 39.8 months. The 3-year DFS rates were 44.1% and 69.7% for Groups 1 and 2, respectively (P = 0.003). The 3-year OS rates were 61.7% and 72.5% for Groups 1 and 2, respectively (P = 0.226). We also analyzed the DFS with each stage, and the results showed a lower DFS rate for T2 and N0 stages. Conclusion: There was no significant survival benefit for MIBC with either RC or TMT. However, RC is associated with better outcome of DFS rate, especially for patients with early stages of MIBC in stages T2 and N0. |
| 關聯: | UROL SCI, v.32, n.4, pp.164-170 |
| 顯示於類別: | [生物科技系(所)] 期刊論文
|
文件中的檔案:
| 檔案 |
描述 |
大小 | 格式 | 瀏覽次數 |
|---|
| index.html | | 0Kb | HTML | 158 | 檢視/開啟 | | UROS.UROS_8_21.pdf | | 1075Kb | Adobe PDF | 72 | 檢視/開啟 |
|
在CNU IR中所有的資料項目都受到原著作權保護.
|
